Economic burden of non-transfusion-dependent thalassemia in the United States
Abstract
To assess all-cause healthcare resource utilization (HCRU) and costs among patients with α- or β-non-transfusion-dependent thalassemia (NTDT) vs. matched controls in the United States. Adults with ≥1 inpatient setting or ≥2 outpatient settings claims for α- or β‑thalassemia between January 1, 2013 and June 30, 2021 were identified from the Merative MarketScan Commercial/Medicare database. Patients with
Fields of Study & Subjects
Hemoglobinopathies and Related Disorders
Health Systems
Economic Evaluations
Quality of Life
Iron Metabolism and Disorders
Publication details
- Journal / source
- Figshare
- Publication date
- 1 January 2026